Addus HomeCare Corporation (ADUS)vsAstraZeneca PLC (AZN)
ADUS
Addus HomeCare Corporation
$92.10
+2.68%
HEALTHCARE · Cap: $1.83B
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 4073% more annual revenue ($60.44B vs $1.45B). AZN leads profitability with a 17.2% profit margin vs 6.9%. ADUS appears more attractively valued with a PEG of 0.96. AZN earns a higher WallStSmart Score of 64/100 (C+).
ADUS
Buy60
out of 100
Grade: C+
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-7.7%
Fair Value
$104.58
Current Price
$92.10
$12.48 premium
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
6.9% margin — thin
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ADUS
The strongest argument for ADUS centers on Altman Z-Score, Debt/Equity, PEG Ratio. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ADUS
The primary concerns for ADUS are Market Cap, Profit Margin.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ADUS profiles as a value stock while AZN is a mature play — different risk/reward profiles.
ADUS carries more volatility with a beta of 0.92 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 60/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Addus HomeCare Corporation
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Addus HomeCare Corporation, provides personal care services to the elderly, the chronically ill, the disabled, and people who are at risk of hospitalization or institutionalization in the United States. The company is headquartered in Frisco, Texas.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?